TriangleDaratumumab SC (NCT05907759)
Daratumumab SC trial for Lymphoma, Primary Effusion (NCT05907759). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–120 with primary effusion lymphoma, plasmablastic lymphoma or symptomatic KSHV-associated multicentric Castleman disease. Disease must relapse or resist frontline treatment, or frontline chemotherapy is unsuitable. HIV is not required.
The idea: use daratumumab to target CD38-bearing cells for destruction. Injections under the skin start weekly for eight weeks. Later frequency and duration differ between lymphoma and Castleman disease, and depend on response. Researchers measure responses. Assessments may require fluid sampling or biopsy.
This phase 2 study plans 40 patients. Robert Yarchoan leads at NIH’s recruiting Bethesda site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.